Hanyu Pharmaceutical: Liraglutide Injection Approved for Market Launch

Han Yu Pharmaceutical announced that the company recently received the "Drug Registration Certificate" for Liraglutide Injection issued by the National Medical Products Administration, with the approval number of National Drug Standard H20260049, classified as a class 2.2 chemical drug produced domestically. This drug is suitable for adult type 2 diabetes patients to control blood sugar levels, etc. It is the first domestically produced fully chemically synthesized formulation of Liraglutide, which was first marketed and commercialized in the United States in December 2024. However, there is a risk of sales not meeting expectations after the drug is launched.